In clinical trials, 75% of the cancer patients with metastatic bone disease who received Amersham's strontium89-based radiopharmaceutical drug, Metastron, experienced a reduction in pain, with 25%-30% of patients reporting complete pain relief, according to Arnold Porter of Harper Hospital in Detroit, USA. Metastron was recently approved for second-line treatment of these patients in the USA (Marketletter June 28). It was first licensed in 1989.
Metastron is marketed and promoted by Amersham Healthcare (also known as Medi-Physics) in the USA, and the company has a worldwide copromotion agreement with Zeneca for this product, which is now launched in 15 countries.
Speaking at a conference entitled Multi-disciplinary Approaches to the Management of Patients with Metastatic Disease, Dr Porter said that the duration of pain relief with Metastron, which averaged up to six months following a single out-patient administration, makes Metastron a major advance over other approaches. In addition, the cost of treating patients appears to be comparable or possibly less than with other therapies, such as injectable narcotics, which may cost as much as $4,000 per month when given by small, portable pumps.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze